3- (4- (2- (2- chloro- 4- fluorophenyl)- 1- (1H- indazol- 5- yl)but- 1- en- 1- yl)phenyl)acrylic acid

01/01/2016 - "GDC-0810 is currently being evaluated in Phase II clinical studies in women with ER+ breast cancer."
10/01/2023 - "GDC-0810 is a small molecule therapeutic agent having potential to treat breast cancer. "
06/15/2017 - " Design: In a phase I clinical trial of GDC-0810, patients with ER-positive metastatic breast cancer underwent FES PET/CT before beginning therapy and at cycle 2, day 3 of GDC-0810 therapy. "
01/01/2019 - "In conclusion, this study characterized the pharmacokinetic profiles of GDC-0810 in breast cancer patients and demonstrated the utility of CPI in detecting OATP1B-mediated DDIs of a new molecular entity as early as FIH study. "
01/07/2019 - "Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer."

01/01/2023 - "GDC-0810 was safe and tolerable with preliminary anti-tumor activity in heavily pretreated patients with ER + advanced/MBC, with/without ESR1 mutations, highlighting the potential for oral SERDs. "
01/29/2018 - "The purpose of this work is to investigate the effect of microenvironmental pH modulation on the in vitro dissolution rate and oral absorption of GDC-0810, an oral anti-cancer drug, in human. "
10/15/2018 - "GDC-0810, administered orally, was used in Phase I and II clinical studies to treat estrogen receptor positive breast cancers. "
11/01/2018 - "GDC-0810 was under development as an oral anti-cancer drug for the treatment of estrogen receptor-positive breast cancer as a single agent or in combination. "